APA (7th ed.) Citation

John, N., Pathmanandavel, S., Crumbaker, M., Counter, W., Ho, B., Yam, A. O., . . . Emmett, L. (2023). 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy. Journal of Nuclear Medicine, 64(3), 410. https://doi.org/10.2967/jnumed.122.264677

Chicago Style (17th ed.) Citation

John, Nikeith, et al. "177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy." Journal of Nuclear Medicine 64, no. 3 (2023): 410. https://doi.org/10.2967/jnumed.122.264677.

MLA (9th ed.) Citation

John, Nikeith, et al. "177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy." Journal of Nuclear Medicine, vol. 64, no. 3, 2023, p. 410, https://doi.org/10.2967/jnumed.122.264677.